|
|
|
VIENNA, Austria and GAITHERSBURG, Md., May 12 /PRNewswire-FirstCall/ -- Intercell AG (VSE: ICLL) and Iomai Corporation announced today that they have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a fully diluted equity value...
Our Stocks to Watch tomorrow include ActionView International Inc. (OTCBB: AVWI), Iomai Corp. (NASD: IOMI), Pilgrim Petroleum Corp. (OTC: PGPM), MobiClear Inc. (OTCBB: MBIR), Solomon Technologies Inc. (OTCBB: SOLM) and Sino Fibre Communications Inc. (OTCBB: SFBE). ActionView International, Inc....
14 May 2008 - Intercell AG and Iomai Corporation announced that they have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a fully diluted equity value of approximately USD 189 million (EUR 122 million). The transaction has...
NEW YORK (AP) - Shares of Iomai Corp. surged Tuesday after the biotechnology company said vaccine maker Intercell AG offered a buyout deal of $189 million, a sharp premium for the shares. The stock rose $3.42, more than doubling to close at $6.34, approaching Intercell's proposed buyout price of...
Shares of Iomai Corp. surged more than 117 percent after the firm agreed to be acquired by Austrian vaccines maker Intercell AG in a deal valued at about $189 million. Intercell's bid of $6.60 per share marked a hefty premium - about 126 percent - to Iomai's Monday closing price of $2.92, though...
Intercell is planning to acquire the needle-free immunization developer, Iomai, for $189.0 million, or $6.60 a share, in hopes of becoming the international traveler's best friend with a new portfolio of vaccines for voyagers. Shares of Iomai (nasdaq: )'s deal values Iomai's stock at a 126.0%...
Hoping to inject its late-stage pipeline with some fresh prospects, Intercell is planning to acquire the needle-free immunization developer, Iomai, for $189.0 million, or $6.60 a share. Shares of Iomai (nasdaq: )'s deal values Iomai's stock at a 126.0% premium to Monday's closing price of $2.92 a...
Posted on: Tuesday, 13 May 2008, 12:00 CDT Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant,...
GAITHERSBURG, Md. (AP) - Biotechnology company Iomai Corp. said late Monday it is being bought by vaccine developer Intercell AG for about $189 million, as part of that company's effort to expand its late-stage pipeline. The $6.60-per-share deal marks a 126 percent premium from Iomai's closing...
Posted on: Tuesday, 13 May 2008, 06:00 CDT Intercell and Iomai have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for $6.60 per share representing a fully diluted equity value of approximately $189 million. Under the terms of the merger agreement, the...
WASHINGTON (Reuters) - Austrian vaccine maker Intercell said on Monday it was acquiring Maryland- based Iomai Corp , a small biotechnology company trying to develop needle-free vaccines. ... "The deal creates a leading traveler's vaccine portfolio by combining...
Gastrointestinal Symptoms, Finance, Banking & Insurance, Investing & Markets, Transportation, Ownership Changes, Stock Markets, Mergers, Acquisitions & Buyouts, Medicines & Remedies, Pharmaceuticals, Vaccines, Pipeline Transport, Investing, Financial Markets, Diarrhea, Merck KGaA, VSE, Smaller Territories of the UK, Central America, United States of America, North America, Maryland, United Kingdom, Turks and Caicos Islands, Gaithersburg (Maryland), Austria
